Format

Send to

Choose Destination
Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9.

Bisphosphonates in the treatment of osteoporosis.

Author information

1
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Cincinnati VA Medical Center, University of Cincinnati, 3125 Eden Avenue, PO Box 670547, Cincinnati, OH 45267, USA. dima.diab@uc.edu

Abstract

Bisphosphonates are widely used in the treatment of osteoporosis to reduce fracture risk. Because of their long retention time in bone and uncommon side effects, questions have been raised about the optimal duration of therapy. Potential side effects appear to be rare and may not be causally related. Although there is no strong science to guide "drug holidays," there appears to be some lingering antifracture benefit when treatment is stopped, so some time off treatment should be offered to most patients on long-term bisphosphonate therapy. For most patients with osteoporosis, the benefits of treatment outweigh the risks.

PMID:
22877426
DOI:
10.1016/j.ecl.2012.04.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center